<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:media="http://search.yahoo.com/mrss/" >

<channel>
	<title>ARSACS</title>
	<atom:link href="https://arsacs.com/feed/" rel="self" type="application/rss+xml" />
	<link>https://arsacs.com</link>
	<description>Research That Heals</description>
	<lastBuildDate>Wed, 21 Oct 2026 15:31:36 +0000</lastBuildDate>
	<language>en-CA</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://arsacs.com/wp-content/uploads/2021/02/cropped-FAVICON-32x32.png</url>
	<title>ARSACS</title>
	<link>https://arsacs.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>New ARSACS Research by Dr. Mohan Babu</title>
		<link>https://arsacs.com/new-arsacs-research-by-dr-mohan-babu/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Wed, 21 Oct 2026 15:17:44 +0000</pubDate>
				<category><![CDATA[Latest News]]></category>
		<guid isPermaLink="false">https://arsacs.com/?p=27172</guid>

					<description><![CDATA[The Natural Sciences and Engineering Research Council of Canada (NSERC) has published an article highlighting the research of Dr. Mohan Babu and his graduate student, Jade Fisher. Dr. Babu's team is investigating potential drug candidates for ARSACS. Their research includes testing approximately 1,000 FDA-approved compounds to identify promising candidates. An interesting article to read! Read [...]]]></description>
										<content:encoded><![CDATA[<p>The <a href="https://nserc-crsng.canada.ca/en" target="_blank" rel="noopener">Natural Sciences and Engineering Research Council of Canada</a> (NSERC) has published an article highlighting the research of Dr. Mohan Babu and his graduate student, Jade Fisher.</p>
<p>Dr. Babu&#8217;s team is investigating potential drug candidates for ARSACS. Their research includes testing approximately 1,000 FDA-approved compounds to identify promising candidates.</p>
<p data-pm-slice="1 1 []">An interesting article to read!</p>
<p data-pm-slice="1 1 []"><strong>Read Dr. Babu&#8217;s research report: <a href="https://arsacs.com/wp-content/uploads/2026/10/Scientific-Report_Sep-2026.pdf">Scientific Report_Sep 2026</a></strong><br />
<strong>Discover the article:</strong> <a href="https://nserc-crsng.canada.ca/en/research-stories/capturing-beauty-neurobiology" target="_blank" rel="noopener">Capturing beauty in neurobiology | Natural Sciences and Engineering Research Council of Canada</a></p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Dr. Benoit Gentil to Present ARSACS Research at Montreal Symposium</title>
		<link>https://arsacs.com/dr-benoit-gentil-to-present-arsacs-research-at-montreal-symposium/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Thu, 15 Oct 2026 14:44:07 +0000</pubDate>
				<category><![CDATA[Upcoming Conferences and Events]]></category>
		<category><![CDATA[Latest News]]></category>
		<guid isPermaLink="false">https://arsacs.com/?p=27162</guid>

					<description><![CDATA[On October 19, 2026, Dr. Benoit Gentil, a researcher at McGill University, will present his work on the development of gene therapies for Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS). This presentation will take place during the symposium The Future of Advanced Therapies in Neurology, organized by The Neuro. A wonderful opportunity to highlight ARSACS [...]]]></description>
										<content:encoded><![CDATA[<p>On October 19, 2026, Dr. Benoit Gentil, a researcher at McGill University, will present his work on the development of gene therapies for Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS).</p>
<p>This presentation will take place during the symposium The Future of Advanced Therapies in Neurology, organized by The Neuro.</p>
<p>A wonderful opportunity to highlight ARSACS research and foster scientific exchange!</p>
<p>🔗 Explore the program: <a href="https://cru.mcgill.ca/symposium/program/" target="_blank" rel="noopener">Symposium &#8211; Program &#8211; Neuro CRU</a></p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Newsletter # 8 &#8211; Fall 2026 Edition</title>
		<link>https://arsacs.com/newsletter-8-fall-2026-edition/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Thu, 08 Oct 2026 15:31:08 +0000</pubDate>
				<category><![CDATA[Latest News]]></category>
		<guid isPermaLink="false">https://arsacs.com/?p=27140</guid>

					<description><![CDATA[In this fall edition, discover the latest developments in ARSACS research, including the work of Drs. Justin Wolter and Huaxia Wang, as well as the announcement of 11 new research projects funded for 2026–2027. We also look back at the international scientific meeting held in Milan, introduce our new Director of Programs and Communications, Valérie [...]]]></description>
										<content:encoded><![CDATA[<p data-pm-slice="1 1 []">In this fall edition, discover the latest developments in ARSACS research, including the work of Drs. Justin Wolter and Huaxia Wang, as well as the announcement of 11 new research projects funded for 2026–2027.</p>
<p data-pm-slice="1 1 []">We also look back at the international scientific meeting held in Milan, introduce our new Director of Programs and Communications, Valérie Deraiche, and share details about two upcoming events: the 8th International ARSACS Symposium and the 19th Dîner des producteurs.</p>
<p data-pm-slice="1 1 []">Read the <a href="https://arsacs.com/wp-content/uploads/2026/10/Newletter-Fall-2026.pdf">Newletter Fall 2026</a></p>
&nbsp;

<!-- /wp:post-content -->]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>19th edition – Diner des Producteurs</title>
		<link>https://arsacs.com/19th-edition-diner-des-producteurs-2/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Mon, 05 Oct 2026 14:13:26 +0000</pubDate>
				<category><![CDATA[Latest News]]></category>
		<guid isPermaLink="false">https://arsacs.com/?p=27092</guid>

					<description><![CDATA[Under the honorary presidency of Mr. Pierre Miron, Executive Vice-President of iA Groupe financier, the Ataxia Charlevoix-Saguenay Foundation is proud to announce the 19th edition of the Dîner des Producteurs, which will take place on Thursday, November 26, 2026, in Montreal. We will have the honor of welcoming, as special guests, renowned chef Christophe Hay [...]]]></description>
										<content:encoded><![CDATA[




<p class="wp-block-paragraph">Under the honorary presidency of Mr. Pierre Miron, Executive Vice-President of iA Groupe financier, the Ataxia Charlevoix-Saguenay Foundation is proud to announce the 19th edition of the Dîner des Producteurs, which will take place on Thursday, November 26, 2026, in Montreal.</p>
<p class="wp-block-paragraph">We will have the honor of welcoming, as special guests, renowned chef Christophe Hay (Fleur de Loire, France), recipient of two Michelin Stars and one Michelin Green Star, as well as Mr. Thomas Perrin, representative of Famille Perrin, one of France’s most prestigious wine-producing families.</p>
<p class="wp-block-paragraph">Since 2006, the Diner des Producteurs has been the Foundation’s premier fundraising event, supporting research efforts aimed at developing treatments for Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS), a progressive neurological disease.</p>
<p class="wp-block-paragraph"><strong>For more information or to make a reservation, please click on the following links:</strong></p>
<p class="wp-block-paragraph"><a href="https://arsacs.com/wp-content/uploads/2026/06/2026-DDP-Invitation-EN-2.pdf" target="_blank" rel="noreferrer noopener">Invitation</a> and <a href="https://arsacs.com/wp-content/uploads/2026/06/2026-DDP-FORM-EN-1.pdf" target="_blank" rel="noreferrer noopener">Reservation Form</a></p>
<p>&nbsp;</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>A New Step Forward in Understanding SACSIN</title>
		<link>https://arsacs.com/a-new-step-forward-in-understanding-sacsin/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Tue, 22 Sep 2026 14:32:48 +0000</pubDate>
				<category><![CDATA[Latest News]]></category>
		<guid isPermaLink="false">https://arsacs.com/?p=27052</guid>

					<description><![CDATA[A team of Italian researchers has published a new study on SACSIN, the protein involved in ARSACS. For the first time, the researchers have shown that the HEPN domain of SACSIN can bind to RNA, revealing a previously unknown molecular function of the protein. They also observed that an ARSACS-associated mutation, F4574C, reduces this RNA-binding [...]]]></description>
										<content:encoded><![CDATA[<p dir="auto" data-start="320" data-end="694">A team of Italian researchers has published a new study on <strong data-start="275" data-end="285">SACSIN</strong>, the protein involved in ARSACS.</p>
<p dir="auto" data-start="320" data-end="694">For the first time, the researchers have shown that the <strong data-start="376" data-end="417">HEPN domain of SACSIN can bind to RNA</strong>, revealing a previously unknown molecular function of the protein. They also observed that an ARSACS-associated mutation, <strong data-start="540" data-end="550">F4574C</strong>, reduces this RNA-binding activity and alters the behaviour and localization of the HEPN domain in cells.</p>
<p dir="auto" data-start="696" data-end="1069">These findings provide new insight into the cellular mechanisms that may be involved in ARSACS and could, over time, contribute to the development of new therapeutic approaches. The authors emphasize, however, that further research is needed to confirm these observations using full-length SACSIN as well as neuronal and animal models.</p>
<p dir="auto" data-start="1071" data-end="1277">The study, entitled <strong data-start="1091" data-end="1162">“The isolated HEPN domain of SACSIN exhibits RNA-binding activity,”</strong> has been accepted for publication in <em data-start="1200" data-end="1238">Cellular and Molecular Life Sciences</em>.</p>
<p dir="auto" data-start="1279" data-end="1306"><a href="https://doi.org/10.1007/s00018-026-06369-w" target="_blank" rel="noopener"><strong data-start="1279" data-end="1306">Read the full article</strong></a></p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Together, We’re Advancing ARSACS Research — $1M Investment</title>
		<link>https://arsacs.com/together-were-advancing-arsacs-research-1m-investment/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Mon, 14 Sep 2026 22:50:15 +0000</pubDate>
				<category><![CDATA[Latest News]]></category>
		<guid isPermaLink="false">https://arsacs.com/?p=26947</guid>

					<description><![CDATA[The Ataxia Charlevoix-Saguenay Foundation is proud to announce an investment of $1 million in 11 promising ARSACS research projects for 2026–2027. This significant commitment advances our shared mission to deepen our understanding of ARSACS and accelerate the development of effective therapies. We extend our sincere gratitude to the Richardson Trust Fund and the Action for [...]]]></description>
										<content:encoded><![CDATA[




<div>The <strong>Ataxia Charlevoix-Saguenay Foundation</strong> is proud to announce an investment of <strong>$1 million</strong> in <strong>11 promising ARSACS research projects</strong> for 2026–2027. This significant commitment advances our shared mission to deepen our understanding of ARSACS and accelerate the development of effective therapies. We extend our sincere gratitude to the <strong>Richardson Trust Fund</strong> and the <strong>Action for ARSACS Foundation USA (AFA)</strong> for their contributions in jointly funding ARSACS research with the Foundation.  </div>
<div>
<p class="wp-block-paragraph">Congratulations to the dedicated researchers whose projects have been selected for funding. Your innovation and commitment continue to advance scientific knowledge. </p>
</div>
<p><a href="https://arsacs.com/research/"><span style="color: #000000;"><strong>RESEARCH PROJECTS 2026-2027</strong></span></a></p>
<p>&nbsp;</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Investigating Ferroptosis as a Therapeutic Target in ARSACS &#8211; Dr. Currais</title>
		<link>https://arsacs.com/investigating-ferroptosis-as-a-therapeutic-target-in-arsacs/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Fri, 11 Sep 2026 13:38:01 +0000</pubDate>
				<category><![CDATA[Current Research]]></category>
		<guid isPermaLink="false">https://arsacs.com/?p=26845</guid>

					<description><![CDATA[This project investigates ferroptosis, a form of regulated cell death associated with oxidative stress and mitochondrial dysfunction, as a potential disease mechanism and therapeutic target in ARSACS.]]></description>
										<content:encoded><![CDATA[<p>The exact molecular changes operating in cells in Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) are not completely understood. Although several cellular alterations have been observed as a consequence of non-functional sacsin protein, how they predispose to neuronal cell death neurons remain unclear. Recent studies have identified a mechanism of cell death called ferroptosis as a possible key player in various neurodegenerative diseases. Ferroptosis is a form of non-apoptotic, regulated cell death that can be triggered by depletion of intracellular glutathione, leading to mitochondrial dysfunction and lethal lipid peroxidation. Sacsin localizes to mitochondria, and mitochondrial damage is also a prominent feature in ARSACS cells. Our preliminary data identify an enrichment for ferroptosis in transcriptomic data from cells that lack sacsin and show that these cells are highly susceptible to inducers of ferroptosis. Therefore, we hypothesize that ferroptosis plays a pathological role in ARSACS. To address our hypothesis, we will investigate the mechanisms underlying the susceptibility of ARSACS cells to ferroptosis (Aim 1), determine the effects of ferroptosis inhibitors, including a drug candidate in clinical trials, on ARSACS pathology in cells (Aim 2), and evaluate markers of ferroptosis in ARSACS brain tissues (Aim 3). Our goal is to provide new insights into the role of ferroptosis in ARSACS, thus potentially accelerating the development of therapies for ARSACS that target this pathway.</p>
<p>Grant: $25,000<br />
Duration: One year</p>
<p><img fetchpriority="high" decoding="async" class="alignleft wp-image-26837 size-medium" src="https://arsacs.com/wp-content/uploads/2026/09/Antonio-Currais-picture-2026-2027-226x300.jpg" alt="Dr. Antonio Jose Martins Currais" width="226" height="300" /><strong data-start="65" data-end="101">Dr. Antonio Jose Martins Currais</strong><br data-start="101" data-end="104" />Auxiliary Researcher (Research)<br data-start="135" data-end="138" />Faculdade de Ciências da Universidade de Lisboa<br data-start="185" data-end="188" />Lisbon, Portugal<br data-start="204" data-end="207" />Contact: <strong data-start="216" data-end="238"><a class="decorated-link cursor-pointer" rel="noopener" data-start="218" data-end="236">ajcurrais@fc.ul.pt</a></strong></p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Identifying Genetic Modifiers That May Influence ARSACS Symptoms &#8211; Dr. Girard</title>
		<link>https://arsacs.com/identifying-genetic-modifiers-that-may-influence-arsacs-symptoms-dr-girard/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Fri, 11 Sep 2026 13:34:44 +0000</pubDate>
				<category><![CDATA[Current Research]]></category>
		<guid isPermaLink="false">https://arsacs.com/?p=26869</guid>

					<description><![CDATA[This project investigates genetic modifiers that may help explain differences in symptoms among people living with ARSACS.]]></description>
										<content:encoded><![CDATA[<p>A variability of symptoms exist among ARSACS patients which suggests that modifier genes might be implicated even among patients from the SLSJ region, and genetic variations rarely act alone. The team has already used genotyping and genealogical data to confirm a founder haplotype Hypothesis: modifier genes, beyond the known SACS variant, are also shared among patients. Hypothesis: modifiers may not strictly follow the same path observed for the primary ARSACS variant but may instead segregate within subsets of related individuals. They will now use regions of IBD instead of SNPs from GWAS to find causal associations with ARSACS.</p>
<p>Grant: $98,314<br />
<strong>This project is jointly funded with the Richardson Trust Fund, contributing $50,000</strong><br data-start="847" data-end="850" />Duration: One year</p>
<p><img decoding="async" class="size-medium wp-image-19244 alignleft" src="https://arsacs.com/wp-content/uploads/2023/10/Simon-Girard--225x300.jpg" alt="" width="225" height="300" srcset="https://arsacs.com/wp-content/uploads/2023/10/Simon-Girard--225x300.jpg 225w, https://arsacs.com/wp-content/uploads/2023/10/Simon-Girard-.jpg 300w" sizes="(max-width: 225px) 100vw, 225px" /><strong data-start="929" data-end="948">Dr. Simon Girard</strong><br data-start="948" data-end="951" />Professor<br data-start="960" data-end="963" />Université du Québec à Chicoutimi<br data-start="996" data-end="999" />555 boul. Université<br data-start="1019" data-end="1022" />Chicoutimi, Quebec G7H 2G1<br data-start="1048" data-end="1051" />Contact: <strong data-start="1060" data-end="1085"><a class="decorated-link cursor-pointer" rel="noopener" data-start="1062" data-end="1083">simon2_girard@uqac.ca</a></strong></p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Targeting Cav2.1 to Restore Purkinje Cell Function in ARSACS &#8211; Dr. Maltecca</title>
		<link>https://arsacs.com/targeting-cav2-1-to-restore-purkinje-cell-function-in-arsacs/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Fri, 11 Sep 2026 13:34:42 +0000</pubDate>
				<category><![CDATA[Current Research]]></category>
		<guid isPermaLink="false">https://arsacs.com/?p=26875</guid>

					<description><![CDATA[This project investigates whether targeting Cav2.1 calcium channels can restore normal Purkinje cell activity and improve disease-related abnormalities in ARSACS models.]]></description>
										<content:encoded><![CDATA[<p>Reduced activity of Purkinje cells appears early in ARSACS and may be an important driver of cerebellar dysfunction and ataxia. Previous research showed that treating ARSACS mice with the mitochondria-targeted antioxidant MitoQ did not correct these firing abnormalities, suggesting that mitochondrial dysfunction alone does not explain the problem. Dr. Maltecca’s team has identified an abnormal accumulation of Cav2.1 calcium channels at the membrane of Purkinje cells, leading to excessive calcium entry and overactivation of KCa2.2 channels. The researchers have also identified two new small molecules that selectively inhibit Cav2.1. This project will test whether targeting Cav2.1 can restore normal Purkinje cell activity and improve disease-related abnormalities in ARSACS models. The findings could establish Cav2.1 inhibition as a targeted therapeutic strategy for ARSACS and potentially inform research on other Cav2.1 gain-of-function disorders.</p>
<p>Grant: $100,000<br />
Duration: One year</p>
<p><img loading="lazy" decoding="async" class="alignleft wp-image-26216 size-medium" src="https://arsacs.com/wp-content/uploads/2026/04/Dr.-Francesca-Maltecca-300x294.jpg" alt="Dr Francesca Maltecca" width="300" height="294" srcset="https://arsacs.com/wp-content/uploads/2026/04/Dr.-Francesca-Maltecca-300x294.jpg 300w, https://arsacs.com/wp-content/uploads/2026/04/Dr.-Francesca-Maltecca-12x12.jpg 12w, https://arsacs.com/wp-content/uploads/2026/04/Dr.-Francesca-Maltecca.jpg 400w" sizes="(max-width: 300px) 100vw, 300px" /><strong data-start="537" data-end="562">Dr. Francesca Maltecca</strong><br data-start="562" data-end="565" />IRCCS Ospedale San Raffaele<br data-start="592" data-end="595" />Milan, Italy<br data-start="607" data-end="610" />Contact: <strong data-start="619" data-end="648"><a class="decorated-link cursor-pointer" rel="noopener" data-start="621" data-end="646">maltecca.francesca@hsr.it</a></strong></p>
<p>&nbsp;</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>&#8220;Developing conditional mouse models and new approaches to treating ARSACS” &#8211; Dr. Strack</title>
		<link>https://arsacs.com/developing-conditional-mouse-models-and-new-approaches-to-treating-arsacs-dr-stefan-strack-2/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Fri, 11 Sep 2026 13:33:17 +0000</pubDate>
				<category><![CDATA[Current Research]]></category>
		<guid isPermaLink="false">https://www.arsacs.com/?p=22700</guid>

					<description><![CDATA[The Sacs knock-out (KO) mouse is a faithful model of ARSACS, displaying ataxia, muscle weakness, cerebellar degeneration, and, as we have recently shown, learning and memory deficits. With this proposal, we seek to pharmacologically rescue motor- and cognitive phenotypes in the Sacs KO model of ARSACS with a drug that raises levels of a second [...]]]></description>
										<content:encoded><![CDATA[
<p>The Sacs knock-out (KO) mouse is a faithful model of ARSACS, displaying ataxia, muscle weakness, cerebellar degeneration, and, as we have recently shown, learning and memory deficits. With this proposal, we seek to pharmacologically rescue motor- and cognitive phenotypes in the Sacs KO model of ARSACS with a drug that raises levels of a second messenger (cAMP) in the brain and that is currently in phase 2 and phase 3 clinical trials for two neurodevelopmental disorders. Second, we propose to develop gene therapy for ARSACS. Third, we have generated a conditional Sacs KO model, which we will use to pinpoint where and when Sacs loss-of-function causes the spectrum of ARSACS symptoms.</p>
<p class="m_-2151711370727717155MsoListParagraph">Grant: 100 000$</p>
<p><strong>This is a jointly founded project with Action for ARSACS Foundation USA (AFA)</strong></p>
<p>Duration:  One year </p>
<p>&nbsp;</p>

<div class="wp-block-media-text is-stacked-on-mobile" style="grid-template-columns: 22% auto;">
<figure class="wp-block-media-text__media"><img loading="lazy" decoding="async" width="150" height="180" class="wp-image-19044 size-full" src="https://arsacs.com/wp-content/uploads/2023/09/Strack.jpg" alt="" /></figure>
<div class="wp-block-media-text__content">
<p class="wp-block-paragraph">Dr Stefan Strack<br />Dept. Neuroscience &amp; Pharmacologie<br />University of lowa Carver College of Medicine<br />2-452 BSB, 51 Newton Rd.<br />lowa City, IA 52242 USA</p>



<p class="wp-block-paragraph">Coordonnées:<a href="mailto:Stefan-strack@uiowa.edu">Stefan-strack@uiowa.edu</a></p>
</div>
</div>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
